TY  - JOUR
AU  - Slamon, D J
AU  - Neven, P
AU  - Chia, S
AU  - Jerusalem, G
AU  - De Laurentiis, M
AU  - Im, S
AU  - Petrakova, K
AU  - Valeria Bianchi, G
AU  - Martín, M
AU  - Nusch, A
AU  - Sonke, G S
AU  - De la Cruz-Merino, L
AU  - Beck, J T
AU  - Ji, Y
AU  - Wang, C
AU  - Deore, U
AU  - Chakravartty, A
AU  - Zarate, J P
AU  - Taran, T
AU  - Fasching, P A
PY  - 2021
DO  - 10.1016/j.annonc.2021.05.353
UR  - http://hdl.handle.net/10668/17976
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer...
LA  - en
KW  - CDK4/6 inhibitor
KW  - advanced breast cancer
KW  - overall survival
KW  - ribociclib
KW  - Adolescent
KW  - Aminopyridines
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Double-Blind Method
KW  - Female
KW  - Fulvestrant
KW  - Humans
KW  - Postmenopause
KW  - Purines
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
TI  - Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
TY  - research article
VL  - 32
ER  -